Endothelial Progenitor Cells in Subclinical Hypothyroidism: The Effect of Thyroid Hormone Replacement Therapy
| Autor: | S.C. Campbell, S. K. Abdul Shakoor, Jolanta U. Weaver, Salman Razvi, Lorna Ingoe, James Shaw, Latika Sibal, Philip Home, A Aldibbiat |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Endothelium Hormone Replacement Therapy Endocrinology Diabetes and Metabolism Clinical Biochemistry CD34 Cell Count Context (language use) Stem cell marker Biochemistry Endocrinology Hypothyroidism Antigens CD Internal medicine medicine Humans AC133 Antigen Progenitor cell Glycoproteins Subclinical infection business.industry Stem Cells Cholesterol HDL Biochemistry (medical) Endothelial Cells Middle Aged Vascular Endothelial Growth Factor Receptor-2 Endothelial stem cell Thyroxine medicine.anatomical_structure embryonic structures cardiovascular system Female Stem cell Peptides business |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 95:319-322 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jc.2009-1421 |
| Popis: | Subclinical hypothyroidism (SCH) is associated with cardiovascular (CV) risk factors, and possibly CV disease. However, its management remains controversial. Endothelial progenitor cells (EPC), expressing both endothelial and stem cell markers, are known to offer a novel CV risk marker.The aim of the study was to ascertain whether EPC count or function is reduced in SCH and whether it improves with T(4) therapy.EPC were studied in peripheral blood by fluorescence-activated cell sorter and following in vitro cultures before and after T(4) together with CV risk factors in 20 SCH and healthy controls (HC).EPC count was measured at baseline and after T(4) replacement in SCH.EPC count was significantly reduced in SCH compared to HC: median (range)-CD133+/VEGFR-2+, 0.09 (0.02-0.44) vs. 0.47 (0.17-2.12), P0.001; CD34+/VEGFR-2+, 0.10 (0.04-0.46) vs. 0.39 (0.11-2.13), P0.001; whereas EPC function was similar. There was a significant positive correlation between CD133+/VEGFR-2+ with free T(4) levels (r = 0.38; P = 0.02); high-density lipoprotein cholesterol levels (r = 0.51; P = 0.001); and negative correlation with TSH concentrations (r = -0.64; P0.001). After adjustment for conventional CV risk factors, SCH predicted lower EPC count, beta coefficient/P value: CD133+/VEGFR-2+ (-0.77/0.001), and CD34+/VEGFR-2+ (-0.71/0.001). In SCH participants, EPC count increased and was similar to HC after T(4); CD133+/VEGFR-2+, 0.32 (0.03-0.94) vs. 0.09 (0.02-0.44), P0.001; and CD34+/VEGFR-2+, 0.26 (0.06-0.88) vs. 0.10 (0.04-0.46), P0.001.SCH predicted lower EPC count, which improved with T(4) treatment, independent of other CV risk factors, providing additional evidence that T(4) replacement may improve CV risk in SCH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|